Valneva SE (VALN): history, ownership, mission, how it works & makes money

A Brief History of Valneva SE (VALN)

Company Formation and Early Years

Valneva SE was established in 2013 through the merger of two biotechnology companies, Vivalis and Intercell. The new entity focused on developing and commercializing vaccines for infectious diseases. The company is headquartered in Lyon, France.

Initial Public Offering

In 2020, Valneva went public on the Euronext Paris stock exchange, raising approximately €100 million through its initial public offering (IPO). The company aimed to expand its research and development capabilities and accelerate its vaccine pipeline.

Key Product Developments

Valneva's lead product candidate, VLA2001, is an inactivated whole virus vaccine for COVID-19. In February 2021, the company announced positive results from its Phase 1/2 clinical trial. Subsequently, in November 2021, Valneva received conditional marketing authorization from the UK Medicines and Healthcare products Regulatory Agency.

Financial Performance

In 2021, Valneva reported revenues of approximately €18 million, a significant increase compared to €8 million in 2020. The company's net loss for 2021 was around €64 million.

Collaborations and Partnerships

Valneva has established partnerships with various organizations, including a collaboration with the UK government for the supply of its COVID-19 vaccine. In 2021, the UK government ordered up to 100 million doses of VLA2001.

Market Expansion and Future Pipeline

Valneva aims to expand its vaccine portfolio beyond VLA2001. The company is developing vaccines for diseases such as Lyme disease and chikungunya. In 2022, Valneva initiated a Phase 3 trial for its Lyme disease vaccine candidate, VLA15, backed by funding of approximately $20 million from the U.S. government.

Stock Performance and Market Capitalization

As of October 2023, Valneva SE's market capitalization is approximately €300 million. The company's stock price has seen fluctuations, with a high of €15.00 and a low of €5.00 in the past year.

Regulatory Matters

Valneva continues to navigate regulatory pathways for its vaccine candidates. In September 2023, the company submitted a marketing authorization application for VLA2001 to the European Medicines Agency.

Conclusion of Timeline Milestones

• 2013: Formation of Valneva SE through merger
• 2020: Initial public offering raising €100 million
• 2021: Conditional marketing authorization in the UK for VLA2001
• 2022: Initiation of Phase 3 trial for VLA15
• 2023: Marketing authorization application submitted to EMA

A Who Owns Valneva SE (VALN)

Ownership Structure

Valneva SE is a publicly traded biotechnology company headquartered in Vienna, Austria, and is listed on the Euronext Paris under the ticker symbol VALN. As of the latest available data, the ownership structure of Valneva is divided among institutional investors, individual shareholders, and company management.

Major Shareholders

The following table outlines the major shareholders of Valneva SE as of the last financial report available in 2023:

Stock Performance

Valneva SE's performance on the stock market has been subject to considerable fluctuation. As of October 2023, Valneva's share price was approximately €5.25.

The stock price has experienced the following notable changes:

• 52-week high: €7.80
• 52-week low: €3.20
• Market capitalization: Approximately €450 million
• Average trading volume: 150,000 shares per day

Institutional Holdings

Institutional ownership plays a significant role in the governance and decision-making processes of Valneva SE. As of the latest figures:

Management Ownership

Management teams often hold shares, which aligns their interests with those of shareholders. The current management team holds approximately 12.3% of Valneva's shares.

Recent Developments

In 2023, Valneva secured several collaborations and partnerships that have impacted its stock performance. These include:

• Partnership with Pfizer for the development of Lyme disease vaccines.
• Collaboration with the European Commission for COVID-19 vaccine distribution.
• Investment from private equity firms amounting to €50 million for pipeline development.

Conclusion on Valneva's Ownership Landscape

The ownership landscape of Valneva SE reflects a mix of institutional investments and significant participation from retail investors, underscoring the company's appeal across various investor categories.

Valneva SE (VALN) Mission Statement

Core Mission

Valneva SE is a biotechnology company focused on developing and commercializing innovative vaccines for infectious diseases. Their mission is to provide patients with safe and effective vaccines that address unmet medical needs, ultimately contributing to global health improvement.

Strategic Objectives

• Develop innovative vaccines to combat infectious diseases.
• Expand their product pipeline through strategic collaborations and partnerships.
• Achieve broad market access to vaccines in both developed and emerging markets.
• Ensure high safety and efficacy standards in all vaccine developments.

Financial Overview

As of 2023, Valneva SE's financial highlights are as follows:

Product Pipeline

Valneva has a robust pipeline focusing on various infectious diseases. The following table highlights their key vaccine candidates:

Partnerships and Collaborations

Valneva actively seeks partnerships to enhance its research and development capabilities. The following are recent collaborations:

• Partnership with Pfizer for the development of a Lyme disease vaccine.
• Collaboration with the European Union for pandemic preparedness initiatives.
• Agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) to develop vaccines against emerging infectious diseases.

Commitment to Sustainability

Valneva is committed to sustainable practices in its operations and product lifecycle. Their sustainability initiatives include:

• Reducing greenhouse gas emissions by 30% by 2025.
• Implementing responsible sourcing for raw materials.
• Investing in community health programs in partnership with local organizations.

Future Goals

Valneva aims to strengthen its position in the vaccine market through:

• Accelerating the development of new vaccines.
• Enhancing operational efficiencies.
• Expanding into new geographic markets.
• Increasing investment in research and development.

How Valneva SE (VALN) Works

Company Overview

Valneva SE is a fully integrated, commercial-stage biotechnology company focused on developing and commercializing innovative vaccines for infectious diseases. Headquartered in Lyon, France, Valneva operates globally with a workforce of around 200 employees as of 2023.

Business Model

Valneva's business model entails several key steps:

• Research & Development: Invests significantly in R&D, with a budget of approximately €30 million for 2023.
• Partnerships: Collaborates with governmental and commercial entities for vaccine development.
• Commercialization: Focuses on bringing viable vaccines to market for both endemic and pandemic diseases.
• Revenue Streams: Generates income through vaccine sales, licensing agreements, and government grants.

Financial Performance

In Q2 2023, Valneva reported revenue of €12.3 million, primarily driven by sales from its commercialized vaccine, VLA2001. The company's expenses in the same quarter amounted to €15.4 million.

Key Products

Valneva specializes in several vaccines:

• VLA2001: Inactivated, adjuvanted vaccine for COVID-19.
• IXIARO: Vaccine for Japanese Encephalitis.
• VLA1553: Vaccine candidate for chikungunya, currently in Phase 3 trials.

Market Strategy

Valneva's strategy focuses on:

• Targeting niche markets with high unmet medical needs.
• Leveraging existing relationships with health authorities and regulators.
• Expanding the product pipeline through partnerships and acquisitions.

Recent Developments

In September 2023, Valneva announced an agreement with the UK government for the supply of VLA2001, potentially worth €30 million. Additionally, Valneva's stock was trading at approximately €7.50 per share as of mid-October 2023.

Research Collaborations

Valneva collaborates with prestigious institutions and governments. Some significant partnerships include:

• Collaboration with the UK Government for COVID-19 vaccine development.
• Partnership with the European Union for infectious disease vaccine innovation.

Investment and Growth

Valneva is actively seeking investments to enhance its research capabilities. In 2023, the company aimed to raise €50 million through equity financing to support ongoing and future vaccine development projects.

How Valneva SE (VALN) Makes Money

Product Revenue

Valneva SE generates revenue primarily through the sales of its vaccine products. The company is involved in the development and commercialization of vaccines for infectious diseases. Notable products include:

• VLA2001: This is Valneva's inactivated COVID-19 vaccine, which received Conditional Marketing Authorization from the UK in April 2021 and from the European Medicines Agency in December 2021.
• VLA1553: A single-dose chikungunya vaccine that has shown promising phase 3 trial results.

In the fiscal year 2022, Valneva reported product revenue of approximately €43.3 million, primarily from VLA2001 sales.

Partnerships and Collaborations

Valneva has established various collaborations with global pharmaceutical companies, which also contribute to its revenue streams. These partnerships often include milestone payments, research funding, and royalties on product sales. Some significant collaborations include:

• Collaboration with Pfizer: This partnership is focused on developing and commercializing the chikungunya vaccine, VLA1553.
• Government Contracts: Valneva received €36 million from the UK Government in exchange for vaccine development and production commitments during the pandemic.

Grants and Public Funding

Valneva benefits from various public funding sources and grants aimed at vaccine development. Such funding has included:

• European Union Horizon 2020 Program: Valneva has received funding for various projects within this EU program.
• BARDA Funding: The Biomedical Advanced Research and Development Authority has provided funding to advance vaccine candidates during health emergencies.

Financial Performance

Valneva's financials reflect its operations in the biotechnology sector and include the following key figures from the fiscal year 2022:

Market Expansion Strategies

Valneva focuses on expanding its market presence through:

• Geographical Expansion: The company is actively seeking to enter new markets for both existing and upcoming vaccine products.
• Regulatory Approvals: Efforts to secure regulatory approvals in additional regions to increase product availability.

Conclusion on Revenue Streams

Valneva SE's revenue generation is highly dependent on its product offerings, strategic partnerships, and public funding initiatives. Continuous investments in research and development are pivotal for future growth and market competitiveness.